指南与共识浆细胞疾病

美国血液学会2026年轻链淀粉样变性诊断指南

American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.
指南 / 共识 · Blood Adv · 2026-01-01

该指南由美国血液学会组织多学科专家组制定,共形成12条推荐。血清免疫固定电泳、尿免疫固定电泳和血清游离轻链可提高临床疑诊;诊断可通过替代活检(骨髓活检联合脂肪垫取样)有效完成,特定临床情况下可优先选择靶器官活检。

要点

  • 血清免疫固定电泳、尿免疫固定电泳和血清游离轻链联合检测可提高AL淀粉样变性的临床疑诊。
  • 诊断AL淀粉样变性可通过替代活检有效完成,需同时行骨髓活检和脂肪垫取样。
  • 特定临床情况下,可优先选择靶器官活检进行诊断。

核心结论

  • 血清免疫固定电泳、尿免疫固定电泳和血清游离轻链可提高AL淀粉样变性的临床疑诊。
  • 诊断AL淀粉样变性可通过替代活检有效完成,替代活检需同时行骨髓活检和脂肪垫取样。
  • 特定临床情况下可优先选择靶器官活检。

研究设计与样本

  • ASH组建了多学科指南专家组,包括22名代表不同医学专科的成员和1名患者代表。
  • 专家组使用GRADE方法评估证据并形成推荐,推荐草案经过公开评论。
  • 堪萨斯大学医学中心支持指南制定过程,包括更新或执行系统证据审查(截至2023年3月6日)。

主要发现

  • 专家组就12条推荐达成一致。

关键数值与推荐

  • 共形成12条推荐。

临床怎么用

  • 对临床疑诊AL淀粉样变性的患者,应使用血清免疫固定电泳、尿免疫固定电泳和血清游离轻链以提高疑诊。
  • 诊断AL淀粉样变性可通过替代活检有效完成,替代活检需同时行骨髓活检和脂肪垫取样。
  • 特定临床情况下,可优先选择靶器官活检进行诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Light chain (AL) amyloidosis is a rare disease caused by the misfolding of immunoglobulin light chains produced by a plasma cell dyscrasia. Patients can present with involvement of many organs, including the heart, kidneys, liver, nerves, and other sites, resulting in a high symptom burden. Timely and accurate diagnosis is important to prevent organ failure and improve patient survival. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients and clinicians in the timely and effective diagnosis of AL amyloidosis. METHODS: ASH formed a multidisciplinary guideline panel that included 22 individuals representing various medical specialties (academic and community hematology, nephrology, neurology, cardiology, internal medicine, and pathology) as well as 1 patient representative. The group was balanced to minimize potential bias from conflicts of interest. The University of Kansas Medical Center supported the guideline development process, including updating or performing systematic evidence reviews (up to 6 March 2023). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 12 recommendations. CONCLUSIONS: The use of serum immunofixation, urine immunofixation, and serum free light chains enhances the clinical suspicion of AL amyloidosis. The diagnosis of AL amyloidosis can be made effectively through surrogate biopsies, which require both a bone marrow biopsy and fat-pad sampling; however, target organ biopsies may be favored in certain clinical situations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kukreti V, Seftel M, Aguirre MA, et al. American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis. Blood Adv. 2026. PMID: 41592868. doi:10.1182/bloodadvances.2025017073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。